Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Obesity | Research

Clinically relevant plasma proteome for adiposity depots: evidence from systematic mendelian randomization and colocalization analyses

Authors: Min Cao, Bin Cui

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Background

The accumulation of visceral and ectopic fat comprise a major cause of cardiometabolic diseases. However, novel drug targets for reducing unnecessary visceral and ectopic fat are still limited. Our study aims to provide a comprehensive investigation of the causal effects of the plasma proteome on visceral and ectopic fat using Mendelian randomization (MR) approach.

Methods

We performed two-sample MR analyses based on five large genome-wide association study (GWAS) summary statistics of 2656 plasma proteins, to screen for causal associations of these proteins with traits of visceral and ectopic fat in over 30,000 participants of European ancestry, as well as to assess mediation effects by risk factors of outcomes. The colocalization analysis was conducted to examine whether the identified proteins and outcomes shared casual variants.

Results

Genetically predicted levels of 14 circulating proteins were associated with visceral and ectopic fat (P < 4.99 × 10− 5, at a Bonferroni-corrected threshold). Colocalization analysis prioritized ten protein targets that showed effect on outcomes, including FST, SIRT2, DNAJB9, IL6R, CTSA, RGMB, PNLIPRP1, FLT4, PPY and IL6ST. MR analyses revealed seven risk factors for visceral and ectopic fat (P < 0.0024). Furthermore, the associations of CTSA, DNAJB9 and IGFBP1 with primary outcomes were mediated by HDL-C and SHBG. Sensitivity analyses showed little evidence of pleiotropy.

Conclusions

Our study identified candidate proteins showing putative causal effects as potential therapeutic targets for visceral and ectopic fat accumulation and outlined causal pathways for further prevention of downstream cardiometabolic diseases.
Appendix
Available only for authorised users
Literature
1.
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.PubMedCrossRef
2.
Neeland IJ, Ross R, Despres JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715–25.PubMedCrossRef
3.
Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizaka Y, Oka R, Okada M, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Ann Med. 2012;44(1):82–92.PubMedCrossRef
4.
Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301–13.PubMedCrossRef
5.
Martin S, Sorokin EP, Thomas EL, Sattar N, Cule M, Bell JD, et al. Estimating the effect of liver and pancreas volume and Fat Content on risk of diabetes: a mendelian randomization study. Diabetes Care. 2022;45(2):460–8.PubMedCrossRef
6.
Zhao L, Zhou X, Chen Y, Dong Q, Zheng Q, Wang Y et al. Association of visceral fat area or BMI with arterial stiffness in ideal cardiovascular health metrics among T2DM patients. J Diabetes. 2023.
7.
Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017;16(1):19–34.PubMedCrossRef
8.
Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006;5(10):821–34.PubMedCrossRef
9.
Hruska P, Kucera J, Pekar M, Holeczy P, Mazur M, Buzga M, et al. Proteomic Signatures of Human Visceral and subcutaneous adipocytes. J Clin Endocrinol Metab. 2022;107(3):755–75.PubMedCrossRef
10.
Alfadda AA, Masood A, Al-Naami MY, Chaurand P, Benabdelkamel H. A Proteomics Based Approach reveals Differential Regulation of visceral adipose tissue proteins between metabolically healthy and unhealthy obese patients. Mol Cells. 2017;40(9):685–95.PubMedPubMedCentralCrossRef
11.
Smith GD, Ebrahim S. Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22.PubMedCrossRef
12.
13.
Yao C, Chen G, Song C, Keefe J, Mendelson M, Huan T, et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun. 2018;9(1):3268.PubMedPubMedCentralCrossRef
14.
Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017;8:14357.PubMedPubMedCentralCrossRef
15.
Folkersen L, Fauman E, Sabater-Lleal M, Strawbridge RJ, Franberg M, Sennblad B, et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet. 2017;13(4):e1006706.PubMedPubMedCentralCrossRef
16.
Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science. 2018;361(6404):769–73.PubMedPubMedCentralCrossRef
17.
Zaghlool SB, Sharma S, Molnar M, Matias-Garcia PR, Elhadad MA, Waldenberger M, et al. Revealing the role of the human blood plasma proteome in obesity using genetic drivers. Nat Commun. 2021;12(1):1279.PubMedPubMedCentralCrossRef
18.
Pang Y, Kartsonaki C, Lv J, Fairhurst-Hunter Z, Millwood IY, Yu C, et al. Associations of Adiposity, circulating protein biomarkers, and risk of Major Vascular diseases. JAMA Cardiol. 2021;6(3):276–86.PubMedCrossRef
19.
Goudswaard LJ, Bell JA, Hughes DA, Corbin LJ, Walter K, Davey Smith G, et al. Effects of adiposity on the human plasma proteome: observational and mendelian randomisation estimates. Int J Obes (Lond). 2021;45(10):2221–9.PubMedCrossRef
20.
Han BX, Yan SS, Xu Q, Ni JJ, Wei XT, Feng GJ, et al. Mendelian randomization analysis reveals Causal effects of plasma proteome on body composition traits. J Clin Endocrinol Metab. 2022;107(5):e2133–40.PubMedCrossRef
21.
Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et al. Phenome-wide mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020;52(10):1122–31.PubMedPubMedCentralCrossRef
22.
Liu Y, Basty N, Whitcher B, Bell JD, Sorokin EP, van Bruggen N et al. Genetic architecture of 11 organ traits derived from abdominal MRI using deep learning. Elife. 2021;10.
23.
Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40(3):740–52.PubMedCrossRef
24.
Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res. 2012;21(3):223–42.PubMedPubMedCentralCrossRef
25.
Wagner R, Eckstein SS, Yamazaki H, Gerst F, Machann J, Jaghutriz BA, et al. Metabolic implications of pancreatic fat accumulation. Nat Rev Endocrinol. 2022;18(1):43–54.PubMedCrossRef
26.
Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105–16.PubMedPubMedCentralCrossRef
27.
Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274–83.PubMedPubMedCentralCrossRef
28.
Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50(10):1412–25.PubMedPubMedCentralCrossRef
29.
Kurki MI, Karjalainen J, Palta P, Sipila TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508–18.PubMedPubMedCentralCrossRef
30.
Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9.PubMedPubMedCentralCrossRef
31.
Klimentidis YC, Raichlen DA, Bea J, Garcia DO, Wineinger NE, Mandarino LJ, et al. Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int J Obes (Lond). 2018;42(6):1161–76.PubMedCrossRef
32.
Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51(2):237–44.PubMedPubMedCentralCrossRef
33.
Clarke TK, Adams MJ, Davies G, Howard DM, Hall LS, Padmanabhan S, et al. Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N = 112 117). Mol Psychiatry. 2017;22(10):1376–84.PubMedPubMedCentralCrossRef
34.
Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22(3):343–52.PubMedPubMedCentralCrossRef
35.
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658–65.PubMedPubMedCentralCrossRef
36.
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25.PubMedPubMedCentralCrossRef
37.
Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7.
38.
Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019;35(22):4851–3.PubMedPubMedCentralCrossRef
39.
Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5):e1004383.PubMedPubMedCentralCrossRef
40.
Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019;4:186.PubMedCrossRef
41.
Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, Heron J, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36(5):465–78.PubMedPubMedCentralCrossRef
42.
Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9(383).
43.
Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745–51.PubMedCrossRef
44.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–34.PubMedCrossRef
45.
Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18(8):727–35.PubMedPubMedCentralCrossRef
46.
Carbonaro M, Wang K, Huang H, Frleta D, Patel A, Pennington A, et al. IL-6-GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models. Sci Adv. 2023;9(15):eadf4490.PubMedPubMedCentralCrossRef
47.
Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016;1863(6 Pt A):1218–27.PubMedCrossRef
48.
Michalopoulou M, Nikolaou C, Tavernarakis A, Alexandri NM, Rentzos M, Chatzipanagiotou S, et al. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. Immunol Lett. 2004;94(3):183–9.PubMedCrossRef
49.
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1–20.PubMedPubMedCentralCrossRef
50.
Schele E, Fekete C, Egri P, Fuzesi T, Palkovits M, Keller E, et al. Interleukin-6 receptor alpha is co-localised with melanin-concentrating hormone in human and mouse hypothalamus. J Neuroendocrinol. 2012;24(6):930–43.PubMedCrossRef
51.
Schele E, Benrick A, Grahnemo L, Egecioglu E, Anesten F, Palsdottir V, et al. Inter-relation between interleukin (IL)-1, IL-6 and body fat regulating circuits of the hypothalamic arcuate nucleus. J Neuroendocrinol. 2013;25(6):580–9.PubMedCrossRef
52.
Wunderlich FT, Strohle P, Konner AC, Gruber S, Tovar S, Bronneke HS, et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 2010;12(3):237–49.PubMedCrossRef
53.
Skuratovskaia D, Komar A, Vulf M, Quang HV, Shunkin E, Volkova L et al. IL-6 reduces mitochondrial replication, and IL-6 receptors reduce chronic inflammation in NAFLD and type 2 diabetes. Int J Mol Sci. 2021;22(4).
54.
Li S, Chen L, Lv G. Interleukin-6 receptor blockade can increase the risk of nonalcoholic fatty liver disease: indications from mendelian randomization. Front Pharmacol. 2022;13:905936.PubMedPubMedCentralCrossRef
55.
Livingstone C. Insulin-like growth factor-I (IGF-I) and clinical nutrition. Clin Sci (Lond). 2013;125(6):265–80.PubMedCrossRef
56.
Clemmons DR. Role of IGF binding proteins in regulating metabolism. Trends Endocrinol Metab. 2016;27(6):375–91.PubMedCrossRef
57.
Haywood NJ, Slater TA, Matthews CJ, Wheatcroft SB. The insulin like growth factor and binding protein family: novel therapeutic targets in obesity & diabetes. Mol Metab. 2019;19:86–96.PubMedCrossRef
58.
Gray A, Aronson WJ, Barnard RJ, Mehta H, Wan J, Said J, et al. Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol. 2011;211(3):297–304.PubMedPubMedCentralCrossRef
59.
Hagstrom H, Stal P, Hultcrantz R, Brismar K, Ansurudeen I. IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD - a pilot study. Scand J Gastroenterol. 2017;52(12):1427–34.PubMedCrossRef
60.
Jeyaratnaganthan N, Gronbaek H, Holland-Fischer P, Espelund U, Chen JW, Flyvbjerg A, et al. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum. Clin Endocrinol (Oxf). 2010;72(5):625–32.PubMedCrossRef
61.
Nedic O, Malenkovic V, Dukanovic B, Baricevic I. Association of elevated IGFBP-1 with increased IGF-II concentration in patients with carcinoma of the liver. Int J Biol Markers. 2008;23(4):225–30.PubMedCrossRef
62.
Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood). 2002;227(9):724–52.PubMedCrossRef
63.
Hansen JS, Rutti S, Arous C, Clemmesen JO, Secher NH, Drescher A, et al. Circulating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio. J Clin Endocrinol Metab. 2016;101(2):550–60.PubMedCrossRef
64.
Braga M, Reddy ST, Vergnes L, Pervin S, Grijalva V, Stout D, et al. Follistatin promotes adipocyte differentiation, browning, and energy metabolism. J Lipid Res. 2014;55(3):375–84.PubMedPubMedCentralCrossRef
65.
Tang R, Harasymowicz NS, Wu CL, Collins KH, Choi YR, Oswald SJ, et al. Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet-induced obesity. Sci Adv. 2020;6(19):eaaz7492.PubMedPubMedCentralCrossRef
66.
Polyzos SA, Kountouras J, Anastasilakis AD, Triantafyllou G, Mantzoros CS. Activin A and follistatin in patients with nonalcoholic fatty liver disease. Metabolism. 2016;65(10):1550–8.PubMedPubMedCentralCrossRef
67.
Hansen JS, Plomgaard P. Circulating follistatin in relation to energy metabolism. Mol Cell Endocrinol. 2016;433:87–93.PubMedCrossRef
68.
Zhou XY, van der Spoel A, Rottier R, Hale G, Willemsen R, Berry GT, et al. Molecular and biochemical analysis of protective protein/cathepsin A mutations: correlation with clinical severity in galactosialidosis. Hum Mol Genet. 1996;5(12):1977–87.PubMedCrossRef
69.
Xia Y, Cortez-Retamozo V, Niederkofler V, Salie R, Chen S, Samad TA, et al. Dragon (repulsive guidance molecule b) inhibits IL-6 expression in macrophages. J Immunol. 2011;186(3):1369–76.PubMedCrossRef
70.
71.
Xia Y, Sidis Y, Mukherjee A, Samad TA, Brenner G, Woolf CJ, et al. Localization and action of Dragon (repulsive guidance molecule b), a novel bone morphogenetic protein coreceptor, throughout the reproductive axis. Endocrinology. 2005;146(8):3614–21.PubMedCrossRef
72.
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.PubMedCrossRef
73.
Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteom. 2014;13(2):397–406.CrossRef
74.
Shi Y, Zhong L, Li Y, Chen Y, Feng S, Wang M, et al. Repulsive Guidance Molecule b Deficiency induces gut microbiota dysbiosis and increases the susceptibility to intestinal inflammation in mice. Front Microbiol. 2021;12:648915.PubMedPubMedCentralCrossRef
75.
Lazo M, Zeb I, Nasir K, Tracy RP, Budoff MJ, Ouyang P, et al. Association between Endogenous Sex Hormones and Liver Fat in a multiethnic study of atherosclerosis. Clin Gastroenterol Hepatol. 2015;9:1686–e932.CrossRef
76.
Cai X, Thorand B, Hohenester S, Prehn C, Cecil A, Adamski J, et al. Association of sex hormones and sex hormone-binding globulin with liver fat in men and women: an observational and mendelian randomization study. Front Endocrinol (Lausanne). 2023;14:1223162.PubMedCrossRef
77.
Zhang X, Mou Y, Aribas E, Amiri M, Nano J, Bramer WM, et al. Associations of sex steroids and sex hormone-binding globulin with non-alcoholic fatty liver disease: a population-based study and meta-analysis. Genes (Basel). 2022;6:966.CrossRef
78.
Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Dyer RA, Innis SM, Simo R, et al. Sex hormone-binding globulin reduction in metabolic disorders may play a role in NAFLD development. Endocrinology. 2017;3:545–59.
79.
Yamazaki H, Kushiyama A, Sakoda H, Fujishiro M, Yamamotoya T, Nakatsu Y et al. Protective effect of sex hormone-binding globulin against metabolic syndrome: in vitro evidence showing anti-inflammatory and lipolytic effects on adipocytes and macrophages. Mediators Inflammation. 2018; 2018:3062319.
Metadata
Title
Clinically relevant plasma proteome for adiposity depots: evidence from systematic mendelian randomization and colocalization analyses
Authors
Min Cao
Bin Cui
Publication date
01-12-2024
Publisher
BioMed Central
Keywords
Obesity
Obesity
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02222-1

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue

Research

Association between the stress hyperglycemia ratio and 28-day all-cause mortality in critically ill patients with sepsis: a retrospective cohort study and predictive model establishment based on machine learning

Research

Effects of the stress hyperglycemia ratio on long-term mortality in patients with triple-vessel disease and acute coronary syndrome

Research

Relationships of serum FGF23 and α-klotho with atherosclerosis in patients with type 2 diabetes mellitus

Research

Single-cell insights: pioneering an integrated atlas of chromatin accessibility and transcriptomic landscapes in diabetic cardiomyopathy

Research

Association of non-insulin-based insulin resistance indices with disease severity and adverse outcome in idiopathic pulmonary arterial hypertension: a multi-center cohort study

Research

Sex-specific differences in myocardial glucose metabolic rate in non-diabetic, pre-diabetic and type 2 diabetic subjects
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits